Amphastar Pharmaceuticals, Inc
Price
FilingsNewest: 10-Q, Quarterly reportAug 6 →InsidersNo open-market buys. 3 insiders sold $931,637, 1 of 6 sales on a 10b5-1 plan.→HoldersBlackRock 12.3%Dimensional Fund 5.4%State Street 3.9%→PeersClosest companies: XERS, AXSM, TECX→
From the filings
Figures
- Revenue
- $730.0Mlast 12 months
- Net income
- $78.5Mlast 12 months
- Operating cash flow
- $168.9Mlast 12 months
- Cash and equivalents
- $223.6Mat the last balance sheet
- Total debt
- $612.1Mat the last balance sheet
- Shares outstanding
- 42.5M shareson issue